Background
Joint clinical practice guidelines from the American Urological Association (AUA) and American Society for Radiation Oncology (ASTRO) on adjuvant and salvage radiotherapy after radical prostatectomy. Based on systematic review of evidence through 2012, including SWOG 8794, EORTC 22911, and ARO 96-02.
Interventions and follow up
Arm A: N/A (evidence-based practice guideline)
Arm B: N/A
Primary endpoint: Clinical practice recommendatio
mFollow up: N/A
Arm B: N/A
Primary endpoint: Clinical practice recommendatio
mFollow up: N/A
Results
Key Recommendations: Physicians should offer adjuvant RT to patients with adverse pathologic findings (pT3 disease, positive margins) following RP (Recommendation). Physicians should offer salvage RT to patients with PSA or local recurrence after RP in the absence of distant metastases. PSA should ideally be <1.0 ng/mL before salvage RT. Salvage RT dose ≥64 Gy recommended.
Adverse events
Main adverse events: N/A (guideline document)
Conclusions
Both adjuvant and salvage radiotherapy have roles in post-prostatectomy management. Adjuvant RT is supported by three randomized trials for pT3N0 disease; salvage RT with early initiation (low PSA) yields best outcomes. Shared decision-making is recommended given the trade-off between immediate RT toxicity and delayed recurrence risk.
Key Limitations
Key Limitations: Published before RAVES and RADICALS-RT demonstrated equivalence of adjuvant vs. early salvage approaches, limiting contemporaneity. Recommendations on when to initiate salvage RT have been updated by subsequent trials showing benefit with PSA thresholds as low as 0.1–0.2 ng/mL.
Clinical Context
These guidelines remain the foundational reference for post-prostatectomy RT decision-making in the US. Updated guidance incorporated findings from RAVES, RADICALS-RT, and SPPORT/RTOG 0534, shifting emphasis toward early salvage RT with individualized use of ADT and pelvic nodal irradiation.
References